Identification of mTORC2 as a necessary component of HRG/ErbB2-dependent cellular transformation

Molecular Cancer Research

Volumn 12, Issue 6, 2014, Pages 940-952

  Lin, Miao Chong J ^a   Rojas, Katherine S ^a   Cerione, Richard A ^a   Wilson, Kristin F ^a  

^a Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INK 128; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NEU DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; RAPAMYCIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CELL TRANSFORMATION; COLONY FORMATION; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG SCREENING; HUMAN; HUMAN CELL; MCF 7 CELL LINE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; GENETICS; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; NEUREGULIN-1; PHOSPHORYLATION; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84902688156     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0555     Document Type: Article

References (50)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82. (Pubitemid 17231334)
2. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:07-12.
3. Carraway KL 3rd, Sliwkowski MX, Akita R, Platko JV, Guy PM, Nuijens A, et al. The erbB3 gene product is a receptor for heregulin. J Biol Chem 1994;269:14303-6. (Pubitemid 24191194)
4. Jones JT, Ballinger MD, Pisacane PI, Lofgren JA, Fitzpatrick VD, Fairbrother WJ, et al. Binding interaction of the heregulinbeta EGF domain with ErbB3 and ErbB4 receptors assessed by alanine scanning mutagenesis. J Biol Chem 1998;273:11667-74. (Pubitemid 28272068)
5. Montero JC, Rodriguez-Barrueco R, Ocana A, Diaz-Rodriguez E, Esparis-Ogando A, Pandiella A. Neuregulins and cancer. Clin Cancer Res 2008;14:3237-41.
6. Wilson TR, Lee DY, Berry L, Shames DS, Settleman J. Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell 2011;20:158-72.
7. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009;9:463-75.
8. Nahta R, O'Regan RM. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway. Clin Breast Cancer 2010;10:S72-8.
9. Chen FL, Xia W, Spector NL. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Clin Cancer Res 2008;14:6730-34.
10. Gajria D, Chandarlapaty S. HER2-ampli fied breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev. Anticancer Ther 2011;11:263-75.
11. Ly TK, Wang J, Pereira R, Rojas KS, Peng X, Feng Q, et al. Activation of the Ran GTPase is subject to growth factor regulation and can give rise to cellular transformation. J Biol Chem 2010;285:5815-26.
12. Wilson KF, Fortes P, Singh US, Ohno M, Mattaj IW, Cerione RA. The nuclear cap-binding complex is a novel target of growth factor receptor-coupled signal transduction. J Biol Chem 1999;274:4166-73.
13. Dias SM, Wilson KF, Rojas KS, Ambrosio AL, Cerione RA. The molecular basis for the regulation of the cap-binding complex by the importins. Nat Struct Mol Biol 2009;16:930-7.
14. Milano SK, Kwon W, Pereira R, Antonyak MA, Cerione RA. Characterization of a novel activated Ran GTPase mutant and its ability to induce cellular transformation. J Biol Chem 2012;287:24955-66.
15. Kurisetty VV, Johnston PG, Johnston N, Erwin P, Crowe P, Fernig DG, et al. RAN GTPase is an effector of the invasive/metastatic phenotype induced by osteopontin. Oncogene 2008;27:71-49.
16. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22. (Pubitemid 47001784)
17. Polak P, Hall MN. mTOR and the control of whole body metabolism. Curr Opin Cell Biol 2009;21:209-18.
18. Wang X, Proud CG. mTORC1 signaling: what we still don't know. J Mol Cell Biol 2010;3:206-20.
19. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006;22:159-68.
20. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004;14:1296-302. (Pubitemid 38991819)
21. Yang Q, Inoki K, Ikenoue T, Guan KL. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev 2006;20:2820-32. (Pubitemid 44771744)
22. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002;110:163-75. (Pubitemid 34876545)
23. Jacinto E, Loewith R, Schmidt A, Lin S, Rüegg MA, Hall A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004;6:1122-8. (Pubitemid 39468014)
24. Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen JH, et al. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 2009;15:148-59.
25. Sparks CA, Guertin DA. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 2010;29:3733-44.
26. Vanhaesebroeck B, Alessi DR. The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 2000;346:561-76. (Pubitemid 30171014)
27. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, et al.Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996;15:6541 -51.
28. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switch-board controlling cell growth. Biochem J 2008;412:179-90. (Pubitemid 351758225)
29. Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. Rheb binds and regulates the mTOR kinase. Curr Biol 2005;15:702-13. (Pubitemid 40599924)
30. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, et al. The translational landscape ofmTOR signalling steers cancer initiation and metastasis. Nature 2012;485:55-61.
31. Yang C, Klein EA, Assoian RK, Kazanietz MG. Heregulin beta1 promotes breast cancer cell proliferation through Rac/ERK-dependent induction of cyclin D1 and p21Cip1. Biochem J 2008;410:167-75. (Pubitemid 351300336)
32. Falls DL. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 2003;284:14-30 (Pubitemid 36335807)
33. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-8. (Pubitemid 43259931)
34. Alessi DR, Caudwell FB, Andjelkovic M, Hemmings BA, Cohen P. Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. FEBS Lett 1996;399:333-8. (Pubitemid 26426877)
35. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-101. (Pubitemid 40262113)
36. Copp J, Manning G, Hunter T. TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res 2009;69:1821-7.
37. Peterson RT, Beal PA, Comb MJ, Schreiber SL. FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. J Biol Chem 2000;275:7416-23. (Pubitemid 30146297)
38. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream Cell 2007;129:1261-74. (Pubitemid 46962095)
39. Gan X, Wang J, Su B, Wu D. Evidence for direct activation of mTORC2 kinase activity by phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 2011;286:10998-1002.
40. Huang J, Dibble CC, Matsuzaki M, Manning BD. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol 2008;28:4104-15. (Pubitemid 351812994)
41. Li Y, Corradetti MN, Inoki K, Guan KL. TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem Sci 2004;29:32-8. (Pubitemid 38068478)
42. Huang J, Wu S, Wu CL, Manning BD. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors. Cancer Res 2009;69:6107-14.
43. Ruan SQ,Wang ZH,Wang SW, Fu ZX, Xu KL, Li DB, et al. Heregulin-beta1- induced GPR30 upregulation promotes the migration and invasion potential of SkBr3 breast cancer cells via ErbB2/ErbB3-MAPK/ERK pathway. Biochem Biophys Res Commun 2012;420:385-90.
44. Ruan SQ, Wang SW, Wang ZH, Zhang SZ. Regulation of HRG-beta1-induced proliferation, migration and invasion of MCF-7 cells by upregulation of GPR30 expression. Mol Med Rep 2012;6:131-8.
45. Yang C, Liu Y, Lemmon MA, Kazanietz MG. Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4. Mol Cell Biol 2006;26:831-42. (Pubitemid 43146479)
46. Saci A, Cantley LC, Carpenter CL. Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size. Mol Cell 2011;42:50-61.
47. Hernandez-Negrete I, Carretero-Ortega J, Rosenfeldt H, Hernández-Garcia R, Calderón-Salinas JV, Reyes-Cruz G, et al. P-Rex1 links mammalian target of rapamycin signaling to Rac activation and cell migration. J Biol Chem 2007;282:23708-15. (Pubitemid 47311970)
48. Wertheimer E, Gutierrez-Uzquiza A, Rosembilt C, Lopez-Haber C, Sosa MS, Kazanietz MG. Rac signaling in breast cancer: a tale of GEFs and GAPs. Cell Signal 2012;24:35-62.
49. Garcia-Garcia C, Ibrahim YH, Serra V, Calvo MT, Guzmán M, Grueso J, et al. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin Cancer Res 2012;18:2603-12.
50. Miller TW, Forbes JT, Shah C, Wyatt SK, Manning HC, Olivares MG, et al. Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin Cancer Res 2009;15:7266-76.